Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination Plus Ontak in Metastatic Melanoma
NCT00515528Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Apr 2007
- Primary completion
- Mar 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of denileukin diftitox in melanoma, sponsored by University of Chicago. Started Apr 2007; status: terminated.
02
Drugs
denileukin diftitox
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00515528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515528.